Osiris Discontinues Enrollment In Crohn’s Study Due To Concerns With Trial Design (Medical News Today)

Osiris Therapeutics, Inc. (NASDAQ: OSIR) announced that it has elected to end enrollment at 210 patients in its Phase III trial evaluating Prochymal for Crohn’s disease. The Company believes there is a design flaw in the trial resulting in significantly higher than expected placebo response rates.

Popularity: 23% [?]